Cargando…

Compound Kushen injection attenuates angiotensin II-mediated heart failure by inhibiting the PI3K/Akt pathway

Compound Kushen injection (CKI) is a type of traditional Chinese medicine that has previously been studied for the treatment of various types of cancer. Previous studies have reported that CKI regulates cell apoptosis by downregulating the PI3K/Akt pathway. The present study aimed to determine wheth...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wei, Liu, Da, Yang, Liyun, Chen, Lixia, Miao, Mengdan, Liu, Yongsheng, Yin, Yajuan, Wei, Mei, Liu, Gang, An, Yonghui, Zheng, Mingqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943540/
https://www.ncbi.nlm.nih.gov/pubmed/36734284
http://dx.doi.org/10.3892/ijmm.2023.5226
_version_ 1784891729357307904
author Wang, Wei
Liu, Da
Yang, Liyun
Chen, Lixia
Miao, Mengdan
Liu, Yongsheng
Yin, Yajuan
Wei, Mei
Liu, Gang
An, Yonghui
Zheng, Mingqi
author_facet Wang, Wei
Liu, Da
Yang, Liyun
Chen, Lixia
Miao, Mengdan
Liu, Yongsheng
Yin, Yajuan
Wei, Mei
Liu, Gang
An, Yonghui
Zheng, Mingqi
author_sort Wang, Wei
collection PubMed
description Compound Kushen injection (CKI) is a type of traditional Chinese medicine that has previously been studied for the treatment of various types of cancer. Previous studies have reported that CKI regulates cell apoptosis by downregulating the PI3K/Akt pathway. The present study aimed to determine whether CKI alleviates heart failure (HF) by attenuating cardiomyocyte apoptosis via the inhibition of the PI3K/Akt pathway. Angiotensin II (Ang II) was used to elicit HF, and osmotic minipumps with either Ang II (2 µg/kg/day) or phosphate-buffered saline (PBS; 200 µl) were subcutaneously implanted into 6-week-old male C57BL/6 mice for 3 weeks. In addition, PBS or CKI (25 mg/kg/day) were subcutaneously infused once a day for 3 weeks. Echocardiography was used to examine hemodynamics. The myocardial injury biomarkers, cardiac troponin I and N-terminal (NT)-pro hormone B-type natriuretic peptide, were assessed using enzyme-linked immunosorbent assay. Transmission electron microscopy was used to determine the morphology of the myocardium. The rate of apoptosis was detected using TUNEL staining and flow cytometry (FCM), and the expression levels of apoptosis-related proteins were measured using western blot (WB) analysis. Moreover, H9C2 cells were treated with CKI (2 mg/ml) or LY294002 (an inhibitor of the PI3K/Akt pathway; 25 µmol/l) in combination with Ang II (1 µmol/l) for 48 h. Cell Counting Kit-8 assay, FCM and WB analysis were performed in the H9C2 cells to examine cell viability, cell cycle distribution and representative signaling proteins. It was found that CKI promoted healthy cardiac function, reduced myocardial structural damage and reduced the rate of cardiomyocyte apoptosis. CKI markedly attenuated the expression of apoptosis-related proteins in the PI3K/Akt pathway. The results of the in vitro experiments indicated that CKI promoted cardiomyocyte proliferation and inhibited apoptosis, similar to LY294002. On the whole, the present study demonstrates that CKI reduces cardiomyocyte apoptosis, promotes healthy cardiac function and attenuates Ang II-mediated HF. These ameliorative effects may be associated with the inhibition of the PI3K/Akt pathway.
format Online
Article
Text
id pubmed-9943540
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-99435402023-02-22 Compound Kushen injection attenuates angiotensin II-mediated heart failure by inhibiting the PI3K/Akt pathway Wang, Wei Liu, Da Yang, Liyun Chen, Lixia Miao, Mengdan Liu, Yongsheng Yin, Yajuan Wei, Mei Liu, Gang An, Yonghui Zheng, Mingqi Int J Mol Med Articles Compound Kushen injection (CKI) is a type of traditional Chinese medicine that has previously been studied for the treatment of various types of cancer. Previous studies have reported that CKI regulates cell apoptosis by downregulating the PI3K/Akt pathway. The present study aimed to determine whether CKI alleviates heart failure (HF) by attenuating cardiomyocyte apoptosis via the inhibition of the PI3K/Akt pathway. Angiotensin II (Ang II) was used to elicit HF, and osmotic minipumps with either Ang II (2 µg/kg/day) or phosphate-buffered saline (PBS; 200 µl) were subcutaneously implanted into 6-week-old male C57BL/6 mice for 3 weeks. In addition, PBS or CKI (25 mg/kg/day) were subcutaneously infused once a day for 3 weeks. Echocardiography was used to examine hemodynamics. The myocardial injury biomarkers, cardiac troponin I and N-terminal (NT)-pro hormone B-type natriuretic peptide, were assessed using enzyme-linked immunosorbent assay. Transmission electron microscopy was used to determine the morphology of the myocardium. The rate of apoptosis was detected using TUNEL staining and flow cytometry (FCM), and the expression levels of apoptosis-related proteins were measured using western blot (WB) analysis. Moreover, H9C2 cells were treated with CKI (2 mg/ml) or LY294002 (an inhibitor of the PI3K/Akt pathway; 25 µmol/l) in combination with Ang II (1 µmol/l) for 48 h. Cell Counting Kit-8 assay, FCM and WB analysis were performed in the H9C2 cells to examine cell viability, cell cycle distribution and representative signaling proteins. It was found that CKI promoted healthy cardiac function, reduced myocardial structural damage and reduced the rate of cardiomyocyte apoptosis. CKI markedly attenuated the expression of apoptosis-related proteins in the PI3K/Akt pathway. The results of the in vitro experiments indicated that CKI promoted cardiomyocyte proliferation and inhibited apoptosis, similar to LY294002. On the whole, the present study demonstrates that CKI reduces cardiomyocyte apoptosis, promotes healthy cardiac function and attenuates Ang II-mediated HF. These ameliorative effects may be associated with the inhibition of the PI3K/Akt pathway. D.A. Spandidos 2023-01-30 /pmc/articles/PMC9943540/ /pubmed/36734284 http://dx.doi.org/10.3892/ijmm.2023.5226 Text en Copyright: © Wang et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Wang, Wei
Liu, Da
Yang, Liyun
Chen, Lixia
Miao, Mengdan
Liu, Yongsheng
Yin, Yajuan
Wei, Mei
Liu, Gang
An, Yonghui
Zheng, Mingqi
Compound Kushen injection attenuates angiotensin II-mediated heart failure by inhibiting the PI3K/Akt pathway
title Compound Kushen injection attenuates angiotensin II-mediated heart failure by inhibiting the PI3K/Akt pathway
title_full Compound Kushen injection attenuates angiotensin II-mediated heart failure by inhibiting the PI3K/Akt pathway
title_fullStr Compound Kushen injection attenuates angiotensin II-mediated heart failure by inhibiting the PI3K/Akt pathway
title_full_unstemmed Compound Kushen injection attenuates angiotensin II-mediated heart failure by inhibiting the PI3K/Akt pathway
title_short Compound Kushen injection attenuates angiotensin II-mediated heart failure by inhibiting the PI3K/Akt pathway
title_sort compound kushen injection attenuates angiotensin ii-mediated heart failure by inhibiting the pi3k/akt pathway
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943540/
https://www.ncbi.nlm.nih.gov/pubmed/36734284
http://dx.doi.org/10.3892/ijmm.2023.5226
work_keys_str_mv AT wangwei compoundkusheninjectionattenuatesangiotensiniimediatedheartfailurebyinhibitingthepi3kaktpathway
AT liuda compoundkusheninjectionattenuatesangiotensiniimediatedheartfailurebyinhibitingthepi3kaktpathway
AT yangliyun compoundkusheninjectionattenuatesangiotensiniimediatedheartfailurebyinhibitingthepi3kaktpathway
AT chenlixia compoundkusheninjectionattenuatesangiotensiniimediatedheartfailurebyinhibitingthepi3kaktpathway
AT miaomengdan compoundkusheninjectionattenuatesangiotensiniimediatedheartfailurebyinhibitingthepi3kaktpathway
AT liuyongsheng compoundkusheninjectionattenuatesangiotensiniimediatedheartfailurebyinhibitingthepi3kaktpathway
AT yinyajuan compoundkusheninjectionattenuatesangiotensiniimediatedheartfailurebyinhibitingthepi3kaktpathway
AT weimei compoundkusheninjectionattenuatesangiotensiniimediatedheartfailurebyinhibitingthepi3kaktpathway
AT liugang compoundkusheninjectionattenuatesangiotensiniimediatedheartfailurebyinhibitingthepi3kaktpathway
AT anyonghui compoundkusheninjectionattenuatesangiotensiniimediatedheartfailurebyinhibitingthepi3kaktpathway
AT zhengmingqi compoundkusheninjectionattenuatesangiotensiniimediatedheartfailurebyinhibitingthepi3kaktpathway